O. A. Bernard

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

D. Birnbaum, E. Solary, W. Vainchenker, 2009, Haematologica.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

B. Dörken, C. Schmitt, K. Stamatopoulos, 2017, Leukemia.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P. Vyas, K. Yen, R. Levine, 2018, Nature Medicine.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P. Vyas, K. Yen, R. Levine, 2018, Nature Medicine.